Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Demineralized dentin allograft (DDA) is a regenerative biomaterial derived from processed human donor teeth, primarily utilized in dental and maxillofacial surgery for bone augmentation and alveolar ridge preservation. Biochemically similar to bone, dentin consists of an inorganic mineral phase and an organic matrix rich in Type I collagen and sequestered bioactive molecules, including bone morphogenetic proteins (BMPs) and transforming growth factor-beta (TGF-β). The demineralization process removes the hydroxyapatite component to expose these growth factors, making them bioavailable to the recipient site. DDA functions through both osteoconduction, providing a structural scaffold for host bone growth, and osteoinduction, where released proteins signal the differentiation of mesenchymal stem cells into osteoblasts. It offers a sustainable and scalable alternative to autogenous bone grafts, eliminating donor-site morbidity while maintaining high biocompatibility and effectiveness in maintaining ridge volume post-extraction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on demineralized dentin allograft.